- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.06. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.06. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.05. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.04. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.03. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.03. | CytoMed Therapeutics Ltd - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 28.01. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | 487 | GlobeNewswire (Europe) | SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| CYTOMED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.01. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital | 412 | GlobeNewswire (Europe) | SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 08.12.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology ... | 195 | GlobeNewswire (Europe) | SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 18.11.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India | 769 | GlobeNewswire (Europe) | SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 28.08.25 | CYTOMED THERAPEUTICS LIMITED: Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition | 526 | GlobeNewswire (Europe) | SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,950 | -0,83 % | CLINUVEL PHARMACEUTICALS LIMITED: Becoming a substantial holder | ||
| EDITAS MEDICINE | 2,510 | +2,45 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,360 | -12,37 % | Cardiol Therapeutics GAAP EPS of -C$0.05 | ||
| CELLECTAR BIOSCIENCES | 2,600 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CYTODYN | 0,226 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,842 | +1,26 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 3,888 | -2,11 % | H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook | ||
| DENALI THERAPEUTICS | 21,680 | +2,70 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| CEL-SCI | 1,190 | +0,85 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,052 | +0,96 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $13.6 million in Q2 2026, up 15% over Q1 - - Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer -... ► Artikel lesen | |
| CURIS | 1,639 | +4,42 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,877 | -0,79 % | Guggenheim cuts CytomX stock price target to $14 on model update | ||
| FATE THERAPEUTICS | 2,166 | -2,34 % | Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated... ► Artikel lesen | |
| FAETH THERAPEUTICS | 24,200 | +9.208 % | XFRA 4070: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYBIN | 10,260 | -0,19 % | Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights | - Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment... ► Artikel lesen |
CYTOMED THERAPEUTICS LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+5,93 %) liegt der Kurs bei 0,715 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTOMED THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.